The duration of anticoagulant interruption prior to a surgical procedure is a critical consideration when a patient is taking apixaban. Apixaban, a direct oral anticoagulant, commonly known by its brand name, Eliquis, reduces the risk of blood clots. The necessary cessation period allows the body to restore its natural clotting ability, thereby minimizing the potential for excessive bleeding during and after the surgical intervention. For example, a patient undergoing an elective hip replacement would typically need to discontinue apixaban several days in advance.
Careful management of anticoagulation before surgery is essential to balance the risk of bleeding against the risk of thromboembolic events such as stroke or pulmonary embolism. Historically, warfarin was the primary oral anticoagulant, requiring bridging therapy with injectable agents like heparin. Newer direct oral anticoagulants like apixaban offer advantages such as predictable pharmacokinetics and less need for routine monitoring. The decision regarding the optimal cessation period depends on factors including the bleeding risk associated with the specific surgery, the patient’s renal function, and their individual thromboembolic risk profile.
